CN1523985B - 用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备 - Google Patents

用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备 Download PDF

Info

Publication number
CN1523985B
CN1523985B CN028106814A CN02810681A CN1523985B CN 1523985 B CN1523985 B CN 1523985B CN 028106814 A CN028106814 A CN 028106814A CN 02810681 A CN02810681 A CN 02810681A CN 1523985 B CN1523985 B CN 1523985B
Authority
CN
China
Prior art keywords
cyclodextrin
pharmaceutical composition
angiotensin
cyclodextrins
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028106814A
Other languages
English (en)
Chinese (zh)
Other versions
CN1523985A (zh
Inventor
R·D·S·米兰
R·A·S·多斯桑托斯
F·J·G·弗莱扎德
W·X·德保拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Minas Gerais
Original Assignee
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Minas Gerais filed Critical Universidade Federal de Minas Gerais
Publication of CN1523985A publication Critical patent/CN1523985A/zh
Application granted granted Critical
Publication of CN1523985B publication Critical patent/CN1523985B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN028106814A 2001-04-10 2002-04-09 用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备 Expired - Fee Related CN1523985B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
BRPI0102252-0 2001-04-10
BRPI01022520 2001-04-10
BRPI0102252-0B1A BR0102252B1 (pt) 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
PCT/BR2002/000051 WO2002080910A1 (en) 2001-04-10 2002-04-09 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications

Publications (2)

Publication Number Publication Date
CN1523985A CN1523985A (zh) 2004-08-25
CN1523985B true CN1523985B (zh) 2010-05-12

Family

ID=3947403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028106814A Expired - Fee Related CN1523985B (zh) 2001-04-10 2002-04-09 用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备

Country Status (7)

Country Link
US (4) US7858597B2 (https=)
EP (1) EP1389106A1 (https=)
JP (2) JP4439814B2 (https=)
CN (1) CN1523985B (https=)
BR (1) BR0102252B1 (https=)
CA (1) CA2444145C (https=)
WO (1) WO2002080910A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR20050005437A (ko) 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
US7041832B2 (en) 2002-04-29 2006-05-09 Tava Pharmaceutical Industries, Ltd. Processes for preparing losartan and losartan potassium
KR100554156B1 (ko) 2003-07-26 2006-02-22 학교법인 포항공과대학교 쿠커비투릴 유도체가 응집되어 형성된 나노 입자, 그 나노입자에 약물이 담지된 약제학적 조성물, 및 이들의 제조방법
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin
JP2008530185A (ja) * 2005-02-21 2008-08-07 フラメル・テクノロジー ロサルタンの経口医薬剤形態
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
WO2008052295A1 (en) * 2006-10-30 2008-05-08 Universidade Federal De Minas Gerais Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products
WO2008089532A1 (en) * 2007-01-26 2008-07-31 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
EP2197416A1 (en) * 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
CN108367079B (zh) * 2015-11-12 2022-11-22 灰色视觉公司 用于治疗的聚集性微粒
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CN115175664A (zh) * 2020-03-25 2022-10-11 耶路撒冷希伯来大学伊森姆研究发展有限公司 包含ati受体阻滞剂的脂质体制剂及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS6025967A (ja) 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US5256687A (en) 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03275617A (ja) * 1990-03-22 1991-12-06 Teikoku Seiyaku Co Ltd サイクロデキストリン類包接生理活性物質含有ポリ乳酸類マイクロスフェア及びその製造方法
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HU209658B (en) * 1992-02-21 1994-10-28 Cyclolab Kft Process for producing cyklodextrin inclusion compexes of fatty acids and their alkalimetal salts, as well as aqueous solutions of the complexes, and microbiological culture medium containing the complexes
AT399718B (de) 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5266583A (en) 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
WO1994014421A2 (en) * 1992-12-23 1994-07-07 Saitec S.R.L. Process for preparing controlled release pharmaceutical forms and the forms thus obtained
PT695169E (pt) * 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5728402A (en) 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) 1995-06-19 1995-06-19 Astra Ab Novel medical use
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE69711068T2 (de) 1996-10-29 2002-09-12 MERCK & CO., INC. Verfahren zur kristallisation von losartan
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
ES2154191B1 (es) 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
FR2787330A1 (fr) 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
AU2573800A (en) 1999-02-19 2000-09-04 Takeda Chemical Industries Ltd. Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6178349B1 (en) 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
IT1307265B1 (it) 1999-08-09 2001-10-30 P F C Italiana Srl Speciality Procedimento per la preparazione di prodotti intermedi nella sintesidi lisinopril.
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
胡荣，吴学思，韩智红，吕强，张维东，贾士杰.氯沙坦治疗高血压病的研究.中国新药杂志第9卷 第2期.2000,9(2),第107-108页.
胡荣,吴学思,韩智红,吕强,张维东,贾士杰.氯沙坦治疗高血压病的研究.中国新药杂志第9卷 第2期.2000,9(2),第107-108页. *
黎洪珊，王培玉.β-环糊精衍生物的研究进展及在药剂学上的应用.中国药学杂志第34卷 第4期.1999,34(4),220-223.
黎洪珊,王培玉.β-环糊精衍生物的研究进展及在药剂学上的应用.中国药学杂志第34卷 第4期.1999,34(4),220-223. *

Also Published As

Publication number Publication date
CN1523985A (zh) 2004-08-25
US20110091541A1 (en) 2011-04-21
CA2444145A1 (en) 2002-10-17
JP2004525167A (ja) 2004-08-19
US8293723B2 (en) 2012-10-23
CA2444145C (en) 2009-11-10
JP4439814B2 (ja) 2010-03-24
US20080108575A1 (en) 2008-05-08
US20040171584A1 (en) 2004-09-02
BR0102252B1 (pt) 2013-10-22
EP1389106A1 (en) 2004-02-18
BR0102252A (pt) 2003-01-21
JP2010047611A (ja) 2010-03-04
WO2002080910A1 (en) 2002-10-17
US20130164341A1 (en) 2013-06-27
US7858597B2 (en) 2010-12-28

Similar Documents

Publication Publication Date Title
US8293723B2 (en) Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
US7723304B2 (en) Systems for delivery and release of angiotensin-(1-7)
CN102124023A (zh) 用于疾病治疗的肽Des-[ASP1]-[ALA1],血管紧张素-(1-7)激动剂和药物组合物
JP2016104824A (ja) 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
CN103169664B (zh) 一种rgd肽修饰的双层载药纳米粒及其制备方法
Rajalakshmi et al. Structure-activity relationship of supramolecular compounds in drug delivery
US8653031B2 (en) Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
JP2006517520A (ja) 蛇、特にジャララカの毒腺から分泌されたペプチド類、バソぺプチダーゼ阻害薬、ｅｖａｓｉｎ類、それらの類似体および誘導体からなる薬学組成物の製造法、および用途開発のための関連製品および晩成退行性疾病での使用
WO2007087700A1 (en) Process for the preparation of formulations of angiotensin converting enzyme inhibitors and product
HUP1000215A2 (hu) Nanostrukturált Telmisartant tartalmazó készítmény és eljárás elõállításukra
BRPI0504978B1 (pt) Processo de preparação de compostos entre os antagonistas do receptor at1 e angiotensina-(1-7) seus análogos e/ou misturas desses sistemas, suas composições farmacêuticas e uso dos produtos derivados

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100512

Termination date: 20150409

EXPY Termination of patent right or utility model